<?xml version="1.0" ?>
<document id="72a5995cb9dc08122a069c6b02e72f2894e0b07c">
  <chunk id="72a5995cb9dc08122a069c6b02e72f2894e0b07c.c0" text="Decitabine-Induced Changes in Human Myelodysplastic Syndrome Cell Line SKM-1 Are Mediated by FOXO3A Activation">
    <entity charOffset="36-60" id="72a5995cb9dc08122a069c6b02e72f2894e0b07c.c0.e0" ontology_id="DOID_0050908" text="Myelodysplastic Syndrome" type="disease"/>
    <entity charOffset="52-60" id="72a5995cb9dc08122a069c6b02e72f2894e0b07c.c0.e1" ontology_id="DOID_225" text="Syndrome" type="disease"/>
  </chunk>
  <chunk id="72a5995cb9dc08122a069c6b02e72f2894e0b07c.c1" text="The epigenetic silencing of tumor suppressor genes in myelodysplastic syndromes (MDS) can potentially confer a growth advantage to individual cellular clones. Currently, the recommended treatment for patients with high-risk MDS is the methylation agent decitabine (DAC), a drug that can induce the reexpression of silenced tumor suppressor genes. We investigated the effects of DAC treatment on the myeloid MDS cell line SKM-1 and investigated the role of FOXO3A, a potentially tumor-suppressive transcription factor, by silencing its expression prior to DAC treatment. We found that FOXO3A exists in an inactive, hyperphosphorylated form in SKM-1 cells, but that DAC both induces FOXO3A expression and reactivates the protein by reducing its phosphorylation level. Furthermore, we show that this FOXO3A activation is responsible for the DAC-induced differentiation of SKM-1 cells into monocytes, as well as for SKM-1 cell cycle arrest, apoptosis, and autophagy. Collectively, these results suggest that FOXO3A reactivation may contribute to the therapeutic effects of DAC in MDS.">
    <entity charOffset="81-84" id="72a5995cb9dc08122a069c6b02e72f2894e0b07c.c1.e0" ontology_id="DOID_0060469" text="MDS" type="disease"/>
    <entity charOffset="224-227" id="72a5995cb9dc08122a069c6b02e72f2894e0b07c.c1.e1" ontology_id="DOID_0060469" text="MDS" type="disease"/>
    <entity charOffset="253-263" id="72a5995cb9dc08122a069c6b02e72f2894e0b07c.c1.e2" ontology_id="CHEBI_50131" text="decitabine" type="chemical"/>
    <entity charOffset="273-277" id="72a5995cb9dc08122a069c6b02e72f2894e0b07c.c1.e3" ontology_id="CHEBI_23888" text="drug" type="chemical"/>
    <entity charOffset="407-410" id="72a5995cb9dc08122a069c6b02e72f2894e0b07c.c1.e4" ontology_id="DOID_0060469" text="MDS" type="disease"/>
    <entity charOffset="448-452" id="72a5995cb9dc08122a069c6b02e72f2894e0b07c.c1.e5" ontology_id="CHEBI_50906" text="role" type="chemical"/>
    <entity charOffset="719-726" id="72a5995cb9dc08122a069c6b02e72f2894e0b07c.c1.e6" ontology_id="CHEBI_16541" text="protein" type="chemical"/>
    <entity charOffset="1076-1079" id="72a5995cb9dc08122a069c6b02e72f2894e0b07c.c1.e7" ontology_id="DOID_0060469" text="MDS" type="disease"/>
    <pair e1="72a5995cb9dc08122a069c6b02e72f2894e0b07c.c1.e0" e2="72a5995cb9dc08122a069c6b02e72f2894e0b07c.c1.e2" id="72a5995cb9dc08122a069c6b02e72f2894e0b07c.c1.p0" relation="true"/>
    <pair e1="72a5995cb9dc08122a069c6b02e72f2894e0b07c.c1.e0" e2="72a5995cb9dc08122a069c6b02e72f2894e0b07c.c1.e3" id="72a5995cb9dc08122a069c6b02e72f2894e0b07c.c1.p1" relation="true"/>
    <pair e1="72a5995cb9dc08122a069c6b02e72f2894e0b07c.c1.e0" e2="72a5995cb9dc08122a069c6b02e72f2894e0b07c.c1.e5" id="72a5995cb9dc08122a069c6b02e72f2894e0b07c.c1.p2" relation="true"/>
    <pair e1="72a5995cb9dc08122a069c6b02e72f2894e0b07c.c1.e0" e2="72a5995cb9dc08122a069c6b02e72f2894e0b07c.c1.e6" id="72a5995cb9dc08122a069c6b02e72f2894e0b07c.c1.p3" relation="true"/>
    <pair e1="72a5995cb9dc08122a069c6b02e72f2894e0b07c.c1.e1" e2="72a5995cb9dc08122a069c6b02e72f2894e0b07c.c1.e2" id="72a5995cb9dc08122a069c6b02e72f2894e0b07c.c1.p4" relation="true"/>
    <pair e1="72a5995cb9dc08122a069c6b02e72f2894e0b07c.c1.e1" e2="72a5995cb9dc08122a069c6b02e72f2894e0b07c.c1.e3" id="72a5995cb9dc08122a069c6b02e72f2894e0b07c.c1.p5" relation="true"/>
    <pair e1="72a5995cb9dc08122a069c6b02e72f2894e0b07c.c1.e1" e2="72a5995cb9dc08122a069c6b02e72f2894e0b07c.c1.e5" id="72a5995cb9dc08122a069c6b02e72f2894e0b07c.c1.p6" relation="true"/>
    <pair e1="72a5995cb9dc08122a069c6b02e72f2894e0b07c.c1.e1" e2="72a5995cb9dc08122a069c6b02e72f2894e0b07c.c1.e6" id="72a5995cb9dc08122a069c6b02e72f2894e0b07c.c1.p7" relation="true"/>
    <pair e1="72a5995cb9dc08122a069c6b02e72f2894e0b07c.c1.e2" e2="72a5995cb9dc08122a069c6b02e72f2894e0b07c.c1.e4" id="72a5995cb9dc08122a069c6b02e72f2894e0b07c.c1.p8" relation="true"/>
    <pair e1="72a5995cb9dc08122a069c6b02e72f2894e0b07c.c1.e2" e2="72a5995cb9dc08122a069c6b02e72f2894e0b07c.c1.e7" id="72a5995cb9dc08122a069c6b02e72f2894e0b07c.c1.p9" relation="true"/>
    <pair e1="72a5995cb9dc08122a069c6b02e72f2894e0b07c.c1.e3" e2="72a5995cb9dc08122a069c6b02e72f2894e0b07c.c1.e4" id="72a5995cb9dc08122a069c6b02e72f2894e0b07c.c1.p10" relation="true"/>
    <pair e1="72a5995cb9dc08122a069c6b02e72f2894e0b07c.c1.e3" e2="72a5995cb9dc08122a069c6b02e72f2894e0b07c.c1.e7" id="72a5995cb9dc08122a069c6b02e72f2894e0b07c.c1.p11" relation="true"/>
    <pair e1="72a5995cb9dc08122a069c6b02e72f2894e0b07c.c1.e4" e2="72a5995cb9dc08122a069c6b02e72f2894e0b07c.c1.e5" id="72a5995cb9dc08122a069c6b02e72f2894e0b07c.c1.p12" relation="true"/>
    <pair e1="72a5995cb9dc08122a069c6b02e72f2894e0b07c.c1.e4" e2="72a5995cb9dc08122a069c6b02e72f2894e0b07c.c1.e6" id="72a5995cb9dc08122a069c6b02e72f2894e0b07c.c1.p13" relation="true"/>
    <pair e1="72a5995cb9dc08122a069c6b02e72f2894e0b07c.c1.e5" e2="72a5995cb9dc08122a069c6b02e72f2894e0b07c.c1.e7" id="72a5995cb9dc08122a069c6b02e72f2894e0b07c.c1.p14" relation="true"/>
    <pair e1="72a5995cb9dc08122a069c6b02e72f2894e0b07c.c1.e6" e2="72a5995cb9dc08122a069c6b02e72f2894e0b07c.c1.e7" id="72a5995cb9dc08122a069c6b02e72f2894e0b07c.c1.p15" relation="true"/>
  </chunk>
</document>
